Highlights Abbisko Cayman Limited

Equities

2256

KYG0028A1085

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 08:08:22 16/03/2026 GMT			5-day change	1st Jan Change
12.32 ^HKD	+1.65%		+3.79%	-5.30%

03-16	Abbisko Doses First Patient in Liver Cancer Drug Trial	MT
03-11	Abbisko Drug Receives Rare Pediatric Designation in U.S.	MT

Highlights

03-11	Abbisko Drug Receives Rare Pediatric Designation in U.S.	MT
03-11	Abbisko Cayman says US FDA grants rare pediatric disease designation for FGFR2/3 inhibitor ABSK061	RE
03-03	Abbisko Profit Nearly Doubles in 2025	MT
03-02	Abbisko Cayman Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-10	Abbisko Therapeutics Co., Ltd. Announces First Patient in the Expansion Part of A Global Phase I Study	CI
02-10	Abbisko Drug Secures Fast Track Designation in U.S.	MT
02-10	Abbisko Cayman says FDA grants fast track designation to Abbisko's irpagratinib	RE
01-13	Abbisko Cayman's new drug application for pimicotinib formally accepted by U.S. FDA	RE
01-13	Abbisko Tumor Treatment Pimicotinib Accepted for U.S. Review	MT
01-13	Abbisko Therapeutics Announces FDA Acceptance of the Nda for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor	CI
12-24	Abbisko Unit Gets China Investigational New Drug Clearance for Tumor Drug	MT
12-24	Abbisko Cayman says NMPA clears IND application for unit's Abbisko's Absk141	RE
12-22	Abbisko Cayman says Abbisko Therapeutics' CSF-1R inhibitor Pimicotinib approved by China NMPA	RE
12-01	Abbisko Cayman says U.S. FDA clears IND application for ABSK141	RE
15/09/25	Tranche Update on Abbisko Cayman Limited's Equity Buyback Plan announced on March 3, 2025.	CI
05/08/25	Abbisko's H1 Profit, Revenue Rise	MT
04/08/25	Abbisko Cayman Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
04/08/25	Abbisko Cayman posts H1 revenue RMB 657.1 million	RE
04/08/25	Tranche Update on Abbisko Cayman Limited's Equity Buyback Plan announced on June 18, 2024.	CI
23/06/25	Abbisko Therapeutics Co., Ltd. Completes First Patient Enrollment of Observational Study for the Treatment of Achondroplasia	CI
20/06/25	Abbisko Cayman Limited announces an Equity Buyback for HKD 200 million of its issued share capital.	CI
17/06/25	Abbisko Cayman Limited's Equity Buyback announced on June 18, 2024, has expired with 16,006,000 shares, representing 2.52% for HKD 93.28 million.	CI
15/06/25	Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC	CI
13/06/25	Abbisko Cayman's CEO Boosts Shareholding	MT
10/06/25	Abbisko Cayman Ltd Says China NMPA Acceptance Of NDA For Pimicotinib For Treatment Of TGCT	RE